Physician profile
Sean C Doyle
NPI 1235138751
$7,684.53
in general payments reported to CMS, 2019-2025
63 companies · $990 in 2025
The $990 reported for 2025 was more than what 86% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $864 · 2020: $707 · 2021: $1,127 · 2022: $1,248 · 2023: $1,362 · 2024: $1,387 · 2025: $990.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,365 · Education: $374.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,365.18 |
| Education | $373.97 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,421.91 | 2019-2025 | Vraylar, Ubrelvy, Qulipta |
| Astellas Pharma US INC | $956.96 | 2019-2025 | Veozah |
| Astrazeneca Pharmaceuticals LP | $480.08 | 2019-2025 | Breztri, Farxiga, Airsupra |
| Lilly USA, LLC | $429.11 | 2019-2025 | Jardiance, Mounjaro, Zepbound |
| Teva Pharmaceuticals USA, INC. | $334.20 | 2019-2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $300.59 | 2019-2025 | Jardiance |
| Bayer Healthcare Pharmaceuticals INC. | $262.75 | 2019-2025 | |
| Novo Nordisk INC | $256.68 | 2019-2025 | Rybelsus, Ozempic |
| Supernus Pharmaceuticals, INC. | $244.59 | 2020-2025 | Qelbree, Qelbree |
| Sanofi-Aventis U.S. LLC | $219.31 | 2019-2024 | |
| Janssen Pharmaceuticals, INC | $214.68 | 2019-2024 | Xarelto |
| Pfizer INC. | $195.04 | 2019-2025 | |
| Amgen INC. | $171.24 | 2022-2024 | Repatha, Otezla |
| Glaxosmithkline, LLC. | $170.68 | 2019-2025 | Shingrix, Arexvy |
| Phathom Pharmaceuticals, INC. | $140.07 | 2023-2025 | Voquezna |
Show all 63 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Allergan, INC. | $132.96 | 2019-2020 | |
| Amarin Pharma, INC. | $97.48 | 2019-2021 | |
| Edwards Lifesciences Corporation | $94.52 | 2022-2025 | Edwards Sapien 3 Transcatheter Heart Valve (Thv), Sapien 3 Ultra Resilia |
| Merck Sharp & Dohme LLC | $85.25 | 2020-2025 | Gardasil 9, Capvaxive, Vaxneuvance |
| Boston Scientific Corporation | $77.54 | 2019-2025 | Watchman Flx, Watchman Access System, Wavewriter Alpha Prime 16 |
| Daiichi Sankyo INC. | $76.25 | 2020-2021 | |
| Abbott Laboratories | $72.55 | 2021-2025 | Freestyle Libre 3 |
| Cranial Technologies, INC | $68.08 | 2021-2025 | Doc Band |
| Idorsia Pharmaceuticals US INC | $67.35 | 2022-2023 | Quviviq |
| Ironshore Pharmaceuticals INC. | $66.51 | 2019-2024 | |
| Collegium Pharmaceutical, INC. | $59.65 | 2024 | Xtampza, Belbuca |
| Corium, LLC | $53.25 | 2022-2023 | Azstarys |
| Nestle Healthcare Nutrition INC. | $52.95 | 2020-2023 | |
| Corcept Therapeutics | $52.44 | 2024 | Korlym |
| Mannkind Corporation | $46.34 | 2020 | |
| Sunovion Pharmaceuticals INC. | $41.47 | 2021-2022 | |
| Sumitomo Pharma America, INC. | $41.43 | 2023 | Gemtesa |
| Organon LLC | $40.62 | 2021-2023 | Nexplanon |
| Sanofi Pasteur INC. | $40.06 | 2019-2022 | |
| Viatris Specialty LLC | $39.69 | 2025 | Yupelri |
| Tris Pharma INC | $38.97 | 2023-2025 | Dyanavel Xr |
| Grifols USA, LLC | $37.37 | 2023 | Prolastin-C Liquid |
| Dexcom, INC. | $35.92 | 2021-2025 | Dexcom G6 Transmitter |
| Bausch Health US, LLC | $33.87 | 2024 | Aplenzin |
| Kowa Pharmaceuticals America, INC. | $33.04 | 2022-2023 | Seglentis, Livalo |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $31.09 | 2021-2022 | |
| Novartis Pharmaceuticals Corporation | $30.28 | 2022 | |
| Shield Therapeutics INC | $25.42 | 2023 | Accrufer |
| Indivior INC. | $22.22 | 2024 | Sublocade |
| Urovant Sciences INC | $21.40 | 2022 | |
| Acadia Pharmaceuticals INC | $20.58 | 2024 | Nuplazid |
| Axsome Therapeutics, INC. | $18.22 | 2024 | Sunosi |
| Aimmune Therapeutics, INC. | $17.75 | 2025 | Zenpep |
| Mylan Specialty L.P. | $17.69 | 2019 | |
| Biohaven Pharmaceutical Holding Company LTD. | $16.48 | 2022 | |
| Medtronic, INC. | $16.42 | 2025 | Venaseal |
| Gilead Sciences, INC. | $15.76 | 2019 | |
| C. R. Bard, INC. & Subsidiaries | $15.13 | 2024 | Bd Onclarity |
| Braintree Laboratories, INC. | $14.85 | 2019 | |
| Kyowa Kirin, INC. | $14.69 | 2023 | Crysvita |
| Almatica Pharma LLC | $14.29 | 2023 | Loreev Xr |
| Radius Health, INC. | $14.25 | 2020 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $14.02 | 2024 | Caplyta |
| Dynavax Technologies Corporation | $12.80 | 2022 | |
| Genentech USA, INC. | $12.58 | 2021 | |
| Avanir Pharmaceuticals, INC. | $12.47 | 2019 | |
| Biohaven Pharmaceuticals, INC. | $11.45 | 2021 | |
| Eisai INC. | $11.24 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sean Doyle listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.